News & Progress
Press Releases
- November 26, 2018
Palleon Pharmaceuticals Announces Preclinical Data from EAGLE Platform to be Presented at the AACR Special Conference on Tumor Immunology and Immunotherapy - November 08, 2018
Palleon Pharmaceuticals Announces Preclinical Data from EAGLE Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting - June 21, 2018
Palleon Pharmaceuticals Appoints Lori Hu of Vertex Ventures HC to Board of Directors - December 12, 2017
Palleon Pharmaceuticals Signs Exclusive License Agreement with King’s College London for Intellectual Property Related to Glycoimmune Checkpoints to Treat Cancer - October 04, 2017
Palleon Pharmaceuticals Raises $47.6 million to Develop Glycoimmune Checkpoint Inhibitors, a New Class of Medicines Designed to Overcome Resistance to First-Generation Immuno-Oncology Drugs
Posters & Publications
- Poster
A Novel Immunomodulatory Strategy of Targeting Glyco-Immune Checkpoints with EAGLE Technology
American Association for Cancer Research, November 2018 - Poster
Targeting Tumor Sialylation in Combination with Checkpoint Inhibitors for Cancer Immunotherapy
Society for Immunotherapy of Cancer, November 2018, Poster #676 - Poster
A Novel Immunomodulatory Strategy of Targeting Glyco-Immune Checkpoints with EAGLE Technology
Society for Immunotherapy of Cancer, November 2018, Poster #037 - Publication
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Journal of Clinical Investigation. August 21, 2018.
@Palleon_Pharma • Dec 14, 2018
Why should we care about #glycans? They are one of the fundamental macromolecules that are essential for life - inf… http://0Kc3kvfRTf
@Palleon_Pharma • Dec 13, 2018
#PalleonSAB: Dr. Paul Moss is a professor of hematology at @unibirmingham studying tumor #immunology. Check out his… http://9RHWI4EGza